Table 2 Patient characteristics
Total | |
|---|---|
Age [mean ± standard deviation] | 67 ± 10 years |
Sex [n] | 27 male and 16 female |
No treatment [n] | 22 (51.2%) |
Treatment with Checkpoint inhibitor (Nivolumab, Pembrolizumab+ Axitinib) [n] | 12 (27.9%) |
Treatment with tyrosine kinase inhibitor (Sorafenib, Cabozantinib, Pazopanib, Sunitinib) [n] | 9 (20.9%) |
Metastatic lesions divided by organ systems (total) [n] | 155 |
Pulmonary [n] | 31 (20.0%) |
Lymphatic [n] | 30 (19.4%) |
Osseous [n] | 18 (11.6%) |
Hepatic [n] | 16 (10.3%) |
Adrenal [n] | 13 (8.4%) |
Peritoneal [n] | 12 (7.7%) |
Local [n] | 11 (7.1%) |
Contralateral kidney [n] | 9 (5.8%) |
Soft tissue [n] | 8 (5.2%) |
Pancreatic [n] | 7 (4.5%) |